To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to detect and treat Lyme disease. Their approach uses CRISPR gene editing.

CRISPR Therapeutics shares early autoimmune and lymphoma data for zugo-cel, showing strong responses, manageable safety, and ...

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. CRISPR Therapeutics CRSP now clears that threshold, with a jump from 79 to 82 Tuesday. Please watch the video ...

CRISPR biosensors enable real-time health monitoring with attomolar sensitivity, wearable integration, and multiplex ...

In its most recent earnings release on Nov. 10, CRISPR said that Vertex has been seeing progress in the number of patients (currently around 300) being referred to treatment centers. Vertex sees ...

CRISPR-Cas9 technology has revolutionized biotechnology by providing an efficient, precise, and versatile tool for genome editing. This RNA-guided system allows scientists to target specific DNA ...

Wondering if CRISPR Therapeutics is still a high risk biotech story or a quietly mispriced opportunity? This breakdown will help you decide whether the current share price makes sense for a long term ...

Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with explosive growth potential should consider the biotech industry. Drugmakers ...

A Swiss biotechnology company said it has used the gene-editing technology CRISPR to treat a patient with a dangerous blood disease called beta thalassemia, marking the technology’s first trial run by ...

Gain insights into the U.S. market, valued at $5.9 Billion in 2024, and China, forecasted to grow at an impressive 14.4% CAGR to reach $7.8 Billion by 2030. Discover growth trends in other key regions ...

Detailed price information for Ark Genomic Revolution ETF (ARKG-A) from The Globe and Mail including charting and trades.